Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Currie

Showing results (211-220 of 231) with videos related to

Pageof 24
Sort By:
Clinical Journal of the American Society of Nephrology : CJASN|December 17, 2020
Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical TrialJohn P Hanrahan, Ian H de Boer, George L Bakris, et al.
The American Journal of Gastroenterology|September 19, 2012
A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipationSatish Rao, Anthony J Lembo, Steven J Shiff, et al.
The New England Journal of Medicine|August 12, 2011
Two randomized trials of linaclotide for chronic constipationAnthony J Lembo, Harvey A Schneier, Steven J Shiff, et al.
Journal of Medicinal Chemistry|May 23, 1998
2-Iminohomopiperidinium salts as selective inhibitors of inducible nitric oxide synthase (iNOS)D W Hansen, K B Peterson, M Trivedi, et al.
Science (New York, N.Y.)|January 30, 1970
Laser ranging retro-reflector: continuing measurements and expected resultsC O Alley, R F Chang, D G Currie, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 13, 2020
Swine acute diarrhea syndrome coronavirus replication in primary human cells reveals potential susceptibility to infectionCaitlin E Edwards, Boyd L Yount, Rachel L Graham, et al.
Journal of Neuroinflammation|September 19, 2021
The CNS-penetrant soluble guanylate cyclase stimulator CYR119 attenuates markers of inflammation in the central nervous systemSusana S Correia, Guang Liu, Sarah Jacobson, et al.
Journal of Medicinal Chemistry|January 23, 1998
Substituted 2-iminopiperidines as inhibitors of human nitric oxide synthase isoformsR K Webber, S Metz, W M Moore, et al.
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]|February 10, 2000
Specific inhibitors of inducible nitric oxide synthase: efficacy in a rodent model of sepsisD J Fretland, D L Widomski, C P Anglin, et al.
Diabetologia|December 21, 2019
An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertensionJohn P Hanrahan, Jelena P Seferovic, James D Wakefield, et al.
Pageof 24

Showing results (211-220 of 231) with videos related to

Sort By:
Pageof 24
Clinical Journal of the American Society of Nephrology : CJASN|December 17, 2020
Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical TrialJohn P Hanrahan, Ian H de Boer, George L Bakris, et al.
The American Journal of Gastroenterology|September 19, 2012
A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipationSatish Rao, Anthony J Lembo, Steven J Shiff, et al.
The New England Journal of Medicine|August 12, 2011
Two randomized trials of linaclotide for chronic constipationAnthony J Lembo, Harvey A Schneier, Steven J Shiff, et al.
Journal of Medicinal Chemistry|May 23, 1998
2-Iminohomopiperidinium salts as selective inhibitors of inducible nitric oxide synthase (iNOS)D W Hansen, K B Peterson, M Trivedi, et al.
Science (New York, N.Y.)|January 30, 1970
Laser ranging retro-reflector: continuing measurements and expected resultsC O Alley, R F Chang, D G Currie, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 13, 2020
Swine acute diarrhea syndrome coronavirus replication in primary human cells reveals potential susceptibility to infectionCaitlin E Edwards, Boyd L Yount, Rachel L Graham, et al.
Journal of Neuroinflammation|September 19, 2021
The CNS-penetrant soluble guanylate cyclase stimulator CYR119 attenuates markers of inflammation in the central nervous systemSusana S Correia, Guang Liu, Sarah Jacobson, et al.
Journal of Medicinal Chemistry|January 23, 1998
Substituted 2-iminopiperidines as inhibitors of human nitric oxide synthase isoformsR K Webber, S Metz, W M Moore, et al.
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]|February 10, 2000
Specific inhibitors of inducible nitric oxide synthase: efficacy in a rodent model of sepsisD J Fretland, D L Widomski, C P Anglin, et al.
Diabetologia|December 21, 2019
An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertensionJohn P Hanrahan, Jelena P Seferovic, James D Wakefield, et al.
Pageof 24